CHARLOTTESVILLE, Va., Aug. 04, 2023 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. ADIL ADILW))) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its…Read More
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaqs Minimum Bid Price Requirement and Reduce the Public Float Adial Pharmaceuticals NASDAQADILW Adial Pharmaceuticals NASDAQADIL
